Non-Hodgkin’s Lymphomas, Version 3.2012

Restricted access

These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin’s Lymphomas (NHL) and describe the clinical evidence supporting the updates. The featured updates include changes to the recommendations for treatment options in patients with chronic lymphocytic leukemia (including in elderly or frail patients and patients with poor-risk cytogenetics), guidance surrounding surveillance imaging for follow-up of patients with NHL, and the addition of first-line consolidation options for patients with mantle cell lymphoma.

  • 1

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 2

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 3

    National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012.

    • Search Google Scholar
    • Export Citation
  • 4

    HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376:11641174.

    • Search Google Scholar
    • Export Citation
  • 5

    RobakTDmoszynskaASolal-CelignyP. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol2010;28:17561765.

    • Search Google Scholar
    • Export Citation
  • 6

    EichhorstBGoedeVHallekM. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma2009;50:171178.

  • 7

    EichhorstBFBuschRStilgenbauerS. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood2009;114:33823391.

    • Search Google Scholar
    • Export Citation
  • 8

    FoaRAliettiAGuariniA. A phase II study of chlorambucil rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results [abstract]. Haematologica2011;96(Suppl 2):Abstract 532.

    • Search Google Scholar
    • Export Citation
  • 9

    FoaRCiolliSDi RaimondoF. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment [abstract]. Blood2011;118:Abstract 294.

    • Search Google Scholar
    • Export Citation
  • 10

    HillmenPGribbenJGFollowsGA. Rituximab plus chlorambucil (R-Chlorambucil) as first-line treatment for chronic lymphocytic leukaemia (CLL): final analysis of an open-label phase II study [abstract]Ann Oncol2011;22(Suppl 4):Abstract 120.

    • Search Google Scholar
    • Export Citation
  • 11

    LeoniLMBaileyBReifertJ. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res2008;14:309317.

    • Search Google Scholar
    • Export Citation
  • 12

    StrumbergDHarstrickADollK. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs1996;7:415421.

    • Search Google Scholar
    • Export Citation
  • 13

    KnaufWULissichkovTAldaoudA. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol2009;27:43784384.

    • Search Google Scholar
    • Export Citation
  • 14

    KnaufWULissitchkovTAldaoudA. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract]. Blood2010;116:Abstract 2449.

    • Search Google Scholar
    • Export Citation
  • 15

    KnaufWULissitchkovTAldaoudA. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol2012;159:6777.

    • Search Google Scholar
    • Export Citation
  • 16

    KnaufWULissitchkovTAldaoudA. Bendamustine in the treatment of chronic lymphocytic leukemia-consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract]. Blood2009;114:Abstract 2367.

    • Search Google Scholar
    • Export Citation
  • 17

    FischerKCramerPBuschR. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2012;30:32093216.

    • Search Google Scholar
    • Export Citation
  • 18

    FischerKCramerPBuschR. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2011:35593566.

    • Search Google Scholar
    • Export Citation
  • 19

    OhYKHaCSSamuelsBI. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology1999;210:483486.

    • Search Google Scholar
    • Export Citation
  • 20

    ZinzaniPLStefoniVTaniM. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol2009;27:17811787.

    • Search Google Scholar
    • Export Citation
  • 21

    GuppyAETebbuttNCNormanACunninghamD. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma2003;44:123125.

    • Search Google Scholar
    • Export Citation
  • 22

    LiedtkeMHamlinPAMoskowitzCHZelenetzAD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol2006;17:909913.

    • Search Google Scholar
    • Export Citation
  • 23

    PetrauschUSamarasPHaileSR. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol2010;21:16941698.

    • Search Google Scholar
    • Export Citation
  • 24

    RomagueraJEFayadLRodriguezMA. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol2005;23:70137023.

    • Search Google Scholar
    • Export Citation
  • 25

    GeislerCHKolstadALaurellA. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood2008;112:26872693.

    • Search Google Scholar
    • Export Citation
  • 26

    DamonLEJohnsonJLNiedzwieckiD. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol2009;27:61016108.

    • Search Google Scholar
    • Export Citation
  • 27

    SchaffelRHedvatCVTeruya-FeldsteinJ. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol2010;21:133139.

    • Search Google Scholar
    • Export Citation
  • 28

    RitchieDSSeymourJFGriggAP. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol2007;86:101105.

    • Search Google Scholar
    • Export Citation
  • 29

    PottCHosterEBeldjordK. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract]. Blood2010;116:Abstract 965.

    • Search Google Scholar
    • Export Citation
  • 30

    LacasceASVandergriftJLRodriguezMA. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood2012;119:20932099.

    • Search Google Scholar
    • Export Citation
  • 31

    ChangJEPetersonCChoiS. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol2011;155:190197.

    • Search Google Scholar
    • Export Citation
  • 32

    KahlBSLongoWLEickhoffJC. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol2006;17:14181423.

    • Search Google Scholar
    • Export Citation
  • 33

    Kluin-NelemansJCHosterEWalewskiJ. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma [abstract]. Blood2011;118:Abstract 439.

    • Search Google Scholar
    • Export Citation
  • 34

    Kluin-NelemansHCHosterEHermineO. Treatment of older patients with mantle-cell lymphoma. N Engl J Med2012;367:52531.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 143 143 14
PDF Downloads 29 29 4
EPUB Downloads 0 0 0